MRTX - Mirati Therapeutics, Inc.
| Previous Close | 94.60 |
| Open | 94.42 |
| Bid | 91.90 x 800 |
| Ask | 94.72 x 900 |
| Day's Range | 91.40 - 94.53 |
| 52 Week Range | 55.11 - 132.59 |
| Volume | 196,673 |
| Avg. Volume | 594,352 |
| Market Cap | 3.635B |
| Beta (5Y Monthly) | 2.32 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.73 |
| Earnings Date | Nov 03, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 115.93 |
- PR Newswire
Mirati Therapeutics Announces Initial Data In Renal Cell Carcinoma From Ongoing Investigator Sponsored Clinical Trial Of Sitravatinib In Combination With Nivolumab At The 2020 ASCO Genitourinary Cancers Syposium
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced the presentation of initial data from an ongoing investigator sponsored Phase 1/2 clinical trial of sitravatinib in combination with nivolumab (OPDIVO®) in patients with advanced clear cell renal cell cancer (aCCRCC) who have documented progression on a prior VEGF-targeted therapy. The data were presented today in an oral abstract presentation by Pavlos Msaouel, M.D., Ph.D., Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, at the 2020 ASCO Genitourinary Cancers Symposium in San Francisco, CA.
- PR Newswire
Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the closing of its previously announced underwritten public offering of 3,538,462 shares of its common stock at a public offering price of $97.50 per share. This includes the exercise in full by the underwriters of their option to purchase up to 461,538 additional shares of common stock. The aggregate gross proceeds to Mirati from this offering were approximately $345.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Mirati.
- PR Newswire
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the pricing of an underwritten public offering of 3,076,924 shares of its common stock at a price to the public of $97.50 per share. The aggregate gross proceeds from this offering are expected to be approximately $300.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Mirati. The offering is expected to close on or about January 14, 2020, subject to customary closing conditions. Mirati has also granted the underwriters a 30-day option to purchase up to an additional 461,538 shares of common stock in connection with the public offering. All of the shares are being sold by Mirati.
- Benzinga
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, DBV Announces Positive Peanut Allergy Study Findings, Applied Genetic Soars On Trial Results
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 8.) Allergan plc (NYSE: AGN ): AbbVie Inc ...
- PR Newswire
Mirati Therapeutics Announces Proposed Public Offering of Common Stock
Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced that it intends to offer and sell, subject to market and other conditions, $250.0 million of shares of its common stock in an underwritten public offering. All of the shares are being offered by Mirati. In addition, Mirati expects to grant the underwriters of the offering a 30-day option to purchase up to an additional $37.5 million of shares of its common stock at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- Benzinga
The Daily Biotech Pulse: Xeris Jumps On Positive Data, Mixed Results For Merck's Keytruda-Chemo Combo In Lung Cancer, Intra-Cellular Announces Offering
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 6.) Agile Therapeutics Inc (NASDAQ: AGRX ) ...
- PR Newswire
Mirati Therapeutics Announces Executive Management Changes
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced changes to their executive management team, effective immediately. Mirati continues to accelerate the development of the KRAS and sitravatinib programs through registrational trials and prepare for commercialization which includes growing their world class executive team.
- Simply Wall St.
Here's What We Think About Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) CEO Pay
Charles Baum has been the CEO of Mirati Therapeutics, Inc. (NASDAQ:MRTX) since 2012. This report will, first, examine...
- PR Newswire
Mirati Therapeutics To Present At The 38th Annual J.P. Morgan Healthcare Conference
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 13th at 4:00 p.m. PST/ 7:00 p.m. EST. Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer will provide a corporate update at the conference.
- Insider Monkey
2019 Review: Most Favored Hedge Fund Stocks vs. Mirati Therapeutics, Inc. (MRTX)
It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory “winners” by making a superficial analysis and research that leads to poor performance on aggregate. Since stock returns aren't usually symmetrically distributed and index […]
- Zacks
4 Drug/Biotech Outperformers That May Lose Steam in 2020
Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.
- Zacks
Options Traders Expect Huge Moves in Mirati (MRTX) Stock
Investors need to pay close attention to Mirati (MRTX) stock based on the movements in the options market lately.
- GlobeNewswire
BeiGene Announces Clinical Data on Investigational Anti-PD-1 Antibody Tislelizumab in Combination with Sitravatinib at European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2019
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, and Mirati Therapeutics (MRTX), a clinical-stage targeted oncology company, today announced preliminary data from an ongoing Phase 1b trial of investigational anti-PD-1 antibody tislelizumab in combination with investigational tyrosine kinase inhibitor sitravatinib in patients with platinum-resistant ovarian cancer, which demonstrated antitumor activity and was generally well tolerated. Results from the Phase 1b clinical trial were presented at the 2019 European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress on December 13, 2019 in Geneva, Switzerland.
- Insider Monkey
Hedge Funds Have Never Been This Bullish On Mirati Therapeutics, Inc. (MRTX)
With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the second quarter. One of these stocks was Mirati Therapeutics, Inc. (NASDAQ:MRTX). Mirati Therapeutics, Inc. (NASDAQ:MRTX) shareholders have […]
- PR Newswire
Mirati Therapeutics Presents Data From Ongoing Clinical Trials Of Sitravatinib In Combination With Nivolumab At The SITC 34th Annual Meeting
SAN DIEGO, Nov. 9, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX), a clinical stage targeted oncology company, today announced the presentation of initial data from its ongoing Phase 2 clinical trial of sitravatinib in combination with nivolumab (OPDIVO®) in metastatic urothelial cancer (mUC) patients with documented progression on a platinum-chemotherapy and checkpoint inhibitor. Preliminary results from the ongoing Phase 1 study of neoadjuvant sitravatinib combined with nivolumab in patients with resectable squamous cell carcinoma of the oral cavity (SNOW trial) were also presented in a poster session. "Sitravatinib is a spectrum-selective kinase inhibitor that potently inhibits receptor tyrosine kinases, including TAM family receptors (TYRO3, Axl, Mer), that has the potential to increase responsiveness in patients whose tumors are resistant to checkpoint inhibitors.
- Zacks
Mirati (MRTX) Reports Q3 Loss, Tops Revenue Estimates
Mirati (MRTX) delivered earnings and revenue surprises of -8.66% and 97.60%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Mirati Therapeutics Reports Third Quarter 2019 Financial Results
SAN DIEGO , Nov. 4, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter ended September 30, ...
- Simply Wall St.
The Mirati Therapeutics (NASDAQ:MRTX) Share Price Gained 1921% And Shareholders Are Jubilant
We think that it's fair to say that the possibility of finding fantastic multi-year winners is what motivates many...
- Benzinga
The Daily Biotech Pulse: Mirati Tastes Success With KRAS Inhibitor, Roche-Spark Deal Delayed Further, Morphosys Halts Study
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 28.) AstraZeneca plc (NYSE: AZN ) ( reported positive ...
- PR Newswire
Mirati Therapeutics Presents First Clinical Data Of Phase 1/2 Trial Of MRTX849 At The 2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
- Preliminary Clinical Activity and Favorable Safety Profile Support Dose Expansion - Maximum Tolerated Dose Has Not Yet Been Established - MRTX849 Data Published in 'Cancer Discovery', in Coordination ...
- Reuters
Mirati drug shrinks tumors in some cancer patients in early-stage trial
An experimental drug from Mirati Therapeutics Inc that targets a specific genetic mutation significantly reduced tumor size in 40% of patients with advanced lung and colorectal cancer so far evaluated in a small, early-stage trial, researchers said on Monday. Investors have been keen to see how Mirati's data stacks up against results for a similar drug, AMG510, under development by Amgen Inc. Both target a mutated form of a gene known as KRAS that occurs in around 13% of non-small cell lung cancer cases, 3-5% of colorectal cancers and up to 2% of other solid tumor cancers. Out of 17 patients enrolled in the Phase 1 trial of Mirati's oral drug MRTX849, 12 have been evaluated, including six with lung cancer and four with colorectal cancer.
- Insider Monkey
Mirati Therapeutics, Inc. (MRTX): Are Hedge Funds Right About This Stock?
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Our research shows that most of the stocks that smart money likes historically generate strong risk-adjusted returns. […]
- PR Newswire
Mirati Therapeutics Announces Presentation Of Interim Phase 2 Sitravatinib Data In Urothelial Carcinoma And Oral Cavity Squamous Cell Carcinoma At The SITC 34th Annual Meeting
SAN DIEGO , Oct. 23, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, announced that the Company will have two presentations at the Society for ...
- PR Newswire
Mirati Therapeutics To Present Pre-Clinical And Initial Clinical Data For MRTX849, A KRAS G12C Inhibitor, At The 2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
SAN DIEGO , Oct. 17, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced it will present pre-clinical data and initial clinical data ...
- Benzinga
Biotech Stock On The Radar: Assessing Mirati's Oncology Franchise With An Eye On Multiple Readouts
Mirati Therapeutics Inc (NASDAQ: MRTX ), a thinly traded, smid-cap oncology biotech, is on investors' radars ahead of upcoming conference presentations and data readouts. Mirati is expected to make a late-breaking presentation ...
